NCT00600067 - A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Diabetes

Interventions

DRUG

Phentermine/Topiramate

phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks

DRUG

Placebo

Oral placebo capsules, once daily, 28 weeks

Trial Locations (9)

Research Site, Birmingham

Research Site, Los Angeles

Research Site, San Francisco

Research Site, Spring Valley

Research Site, Walnut Creek

Research Site, Bethesda

Research Site, Austin

Research Site, San Antonio

Research Site, Richmond